Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Inhibrx Biosciences, Inc stake
total: 670
Viking Global Investors INBX trades
- Total transactions:
- 6
- New positions:
- 1
- Added:
- 2
- Reduced:
- 3
- Held since:
- 2020 Q3
- Held for:
- 24 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen holds 1,123,929 Inhibrx Biosciences, Inc (INBX) shares with a market value of roughly $106.49M accounting for 0.30% of the overall portfolio. To date, the estimated cost basis is nearly $19.26 for "buy" trades and estimated average "sell" price is $22.13. Viking Global Investors first purchased INBX in 2020 Q3, initially acquiring about 5.31M shares. Since the initial investment in Inhibrx Biosciences, Inc (INBX), Viking Global Investors has made 5 more transactions.
When did Ole Andreas Halvorsen buy Inhibrx Biosciences, Inc (INBX)?
Ole Andreas Halvorsen first invested in Inhibrx Biosciences, Inc (INBX) in 2020 Q3 at the reported quarter-end price of $18.00 per share.
What's the cost basis of Viking Global Investors's INBX stake?
The estimated cost basis for Inhibrx Biosciences, Inc (INBX) stake is around $19.26 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $19.26
- Weighted AVG sell price:
- $22.13
Ole Andreas Halvorsen's historical trades in Inhibrx Biosciences, Inc
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.30%
|
1,123,929
|
$94.75
|
$106,492,273
|
-21.82% (-313,776)
|
-0.08%
|
|
2025 Q4
|
0.30%
|
1,437,705
|
$79.00
|
$113,578,695
|
-19.58% (-350,000)
|
-0.07%
|
|
2024 Q2
|
0.10%
|
1,787,705
|
$14.17
|
$25,331,780
|
-75.00% (-5,363,121)
|
-0.28%
|
|
2023 Q3
|
0.53%
|
7,150,826
|
$18.35
|
$131,217,657
|
+7.71% (+511,627)
|
+0.04%
|
|
2022 Q4
|
0.82%
|
6,639,199
|
$24.64
|
$163,589,863
|
+25.13% (+1,333,333)
|
+0.16%
|
|
2020 Q3
|
0.35%
|
$18.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.